Wright Medical Group and Tornier NV have won U.S. antitrust approval for their merger on condition that they sell certain assets related to replacement ankle and toe joints, the Federal Trade Commission said on Wednesday.
The companies said when the deal was announced in October 2014 that the proposed transaction would create a company with a combined value of about $3.3 billion.
The deal will be allowed to go ahead on condition that the companies sell Tornier’s U.S. rights and assets related to total ankle replacements and total silastic toe joint replacements used to treat arthritis, the FTC said.
The FTC said that it required the divestitures because Wright has 44 percent of the market for the ankle replacements and Tornier has about 19 percent. They also have big shares of the market to make silastic toe joint replacements, the FTC said.
Full content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Trump Nominates Olivia Trusty for FCC Commissioner Role Ahead of Inauguration
Jan 16, 2025 by
CPI
Lawyers Claim eXp’s Settlement Tactics Hurt Antitrust Case Potential
Jan 16, 2025 by
CPI
Amex GBT Pushes Back Against DOJ Lawsuit Over CWT Acquisition
Jan 16, 2025 by
CPI
Belgium Opens Antitrust Probe into AB InBev’s Market Practices
Jan 16, 2025 by
CPI
Tech Groups Sue CFPB Over New Rule on Digital Wallet Oversight
Jan 16, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – CRESSE Insights
Dec 19, 2024 by
CPI
Effective Interoperability in Mobile Ecosystems: EU Competition Law Versus Regulation
Dec 19, 2024 by
Giuseppe Colangelo
The Use of Empirical Evidence in Antitrust: Trends, Challenges, and a Path Forward
Dec 19, 2024 by
Eliana Garces
Some Empirical Evidence on the Role of Presumptions and Evidentiary Standards on Antitrust (Under)Enforcement: Is the EC’s New Communication on Art.102 in the Right Direction?
Dec 19, 2024 by
Yannis Katsoulacos
The EC’s Draft Guidelines on the Application of Article 102 TFEU: An Economic Perspective
Dec 19, 2024 by
Benoit Durand